Hacker News·4 min read·medium
New HIV vaccine shows unprecedented success in preclinical study
C
codebyaditya
✦AI Summary
A collaborative study between the La Jolla Institute for Immunology and Scripps Research has produced an HIV vaccine that successfully generates broadly neutralizing antibodies in primates. The vaccine works by training B cells to target vulnerable spots on the virus.
LA JOLLA, CA—A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists, and IAVI has the potential to protect humans from developing HIV infection and AIDS. This HIV vaccine is the first to generate a high number of “broadly neutralizing,” virus-fighting antibodies in primates.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in